Affinity Asset Advisors’s Climb Bio CLYM Stock Holding History

Affinity Asset Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.79M	Sell	700,000 -600,000	-46%	-$3.46M	0.25%	70
2025 Q4	$5.2M	Hold	1,300,000	–	–	0.3%	64
2025 Q3	$2.61M	Sell	1,300,000 -200,000	-13%	-$371K	0.23%	69
2025 Q2	$1.86M	Hold	1,500,000	–	–	0.25%	59
2025 Q1	$1.83M	Buy	1,500,000 +1,000,000	+200%	+$1.62M	0.17%	69
2024 Q4	$900K	Sell	500,000 -1,000,000	-67%	-$3.62M	0.12%	71
2024 Q3	$7.63M	Sell	1,500,000 -170,661	-10%	-$1.21M	1.04%	32
2024 Q2	$11.9M	Buy	+1,670,661	New	+$11.1M	1.37%	22

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Affinity Asset Advisors's CLYM Position: Q1 2026 in Review

Affinity Asset Advisors reduced its Climb Bio (CLYM) stake by 46% in Q1 2026, selling an estimated $3.46M and leaving 700,000 shares worth $4.79M. The position accounts for 0.25% of the portfolio, ranked #70.

Affinity Asset Advisors first reported a position in CLYM in Q2 2024 and has held it in 8 quarters since. The position peaked at $11.9M in Q2 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

Affinity Asset Advisors held 700,000 shares of Climb Bio worth $4.79M as of Q1 2026.
Affinity Asset Advisors sold 600,000 Climb Bio shares in Q1 2026, an estimated $3.46M.
Climb Bio made up 0.25% of Affinity Asset Advisors's portfolio in Q1 2026, its #70 holding.
Affinity Asset Advisors first reported a position in Climb Bio in Q2 2024 and has held it in 8 quarters since.
Affinity Asset Advisors's Climb Bio position peaked at $11.9M in Q2 2024.
80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.